We are analyzing https://link.springer.com/article/10.1186/1750-1326-4-8.

Title:
The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease | Molecular Neurodegeneration
Description:
Despite major advances in our understanding of the initiating factors that trigger many neurodegenerative disorders, to date, no novel disease-modifying therapies have been shown to provide significant benefit for patients who suffer from these devastating disorders. As most neurodegenerative disorders are late-onset, slowly progressive, and appear to have long relatively asymptomatic prodromal phases, it is possible that therapies optimally targeting the triggers of these disorders may have limited benefit when treatment is initiated in the symptomatic patient. Such therapies may work in the prodromal phase, or when given prophylactically, but in the symptomatic patient there simply may be too much damage to the neuronal networks to restore functionality by reducing or even eliminating the primary stressor. As functional neuronal demise and overt neuronal death are almost certainly the key factors that mediate the functional impairment, it is clear that preventing neuronal death and dysfunction will have a huge clinical benefit. Unfortunately, we lack a detailed understanding of neuronal death pathways in almost all neurodegenerative disorders. To rationally develop new disease modifying therapies that target steps in the degenerative cascade downstream of the disease trigger will require a number of factors. First, we need to refocus our basic research efforts on identifying the precise steps in the pathological cascade that lead to neuronal death in each neurodegenerative disease and, if possible, determine the relative placement of those events within a potentially very complex cascade. Second, we will need to determine which of these steps are potentially targetable. Finally, we will need to develop novel therapies that interfere with these steps and demonstrate that such therapies alone, or in combination with therapies that target the trigger of these devastating diseases, have clinical benefit.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

disease, neurodegenerative, neuronal, article, diseases, pubmed, therapies, google, scholar, cascade, trigger, therapeutic, death, cas, downstream, models, neurodegeneration, targeting, loss, understanding, dysfunction, clinical, cascades, cell, brain, animal, development, symptoms, patients, prodromal, phase, pathways, studies, neurons, initiating, disorders, triggers, target, steps, pathological, human, based, common, pathology, central, research, factors, develop, efforts, alzheimers,

Topics {✒️}

article download pdf enabled pre-clinical studies gross motor impairments central cholinergic neurons privacy choices/manage cookies extensive neuronal loss related subjects including neuronal loss authors’ original file potential disease-modifying therapies single downstream pathway typical neurodegenerative diseases recognized prodromal phase initial prodromal phase full size image typical neurodegenerative disease underlying disease process prodromal disease phase asymptomatic prodromal phase phase additional pathological typically extensive damage basic research efforts ubiquitin proteasome pathway axonal transport deficits rare neurodegenerative disease functional neuronal demise massive neuronal loss uncommon neurodegenerative diseases biomed central app mouse models full access european economic area multiple brain regions molecular phenotypes amyloid imaging agents visualize amyloid load cognitive-enhancing agents van woert mh aromatic amino acids axonal transport defects significant neuronal loss overt neuronal death preventing neuronal death driving neuronal death basic ad research neuronal loss downstream trends cell biol uncommon neurodegenerative conditions neuronal cell death asymptomatic prodromal phases

Questions {❓}

Andersen JK: Oxidative stress in neurodegeneration: cause or consequence?
How do we dissect the downstream cascades?
In this review series, a panel of experts in the neurodegenerative disease field will address the questions of "What kills neurons in neurodegenerative disease?
Should the field refocus on the mediators of cell death and therapies targeting those pathways?
What kills neurons in neurodegenerative disease?
Yang Y, Herrup K: Cell division in the CNS: protective response or lethal event in post-mitotic neurons?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease
         description:Despite major advances in our understanding of the initiating factors that trigger many neurodegenerative disorders, to date, no novel disease-modifying therapies have been shown to provide significant benefit for patients who suffer from these devastating disorders. As most neurodegenerative disorders are late-onset, slowly progressive, and appear to have long relatively asymptomatic prodromal phases, it is possible that therapies optimally targeting the triggers of these disorders may have limited benefit when treatment is initiated in the symptomatic patient. Such therapies may work in the prodromal phase, or when given prophylactically, but in the symptomatic patient there simply may be too much damage to the neuronal networks to restore functionality by reducing or even eliminating the primary stressor. As functional neuronal demise and overt neuronal death are almost certainly the key factors that mediate the functional impairment, it is clear that preventing neuronal death and dysfunction will have a huge clinical benefit. Unfortunately, we lack a detailed understanding of neuronal death pathways in almost all neurodegenerative disorders. To rationally develop new disease modifying therapies that target steps in the degenerative cascade downstream of the disease trigger will require a number of factors. First, we need to refocus our basic research efforts on identifying the precise steps in the pathological cascade that lead to neuronal death in each neurodegenerative disease and, if possible, determine the relative placement of those events within a potentially very complex cascade. Second, we will need to determine which of these steps are potentially targetable. Finally, we will need to develop novel therapies that interfere with these steps and demonstrate that such therapies alone, or in combination with therapies that target the trigger of these devastating diseases, have clinical benefit.
         datePublished:2009-02-04T00:00:00Z
         dateModified:2009-02-04T00:00:00Z
         pageStart:1
         pageEnd:7
         license:http://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1750-1326-4-8
         keywords:
            Amyotrophic Lateral Sclerosis
            Neurodegenerative Disease
            Neuronal Death
            Therapeutic Development
            Prodromal Phase
            Neurosciences
            Neurology
            Molecular Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1750-1326-4-8/MediaObjects/13024_2008_Article_72_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1750-1326-4-8/MediaObjects/13024_2008_Article_72_Fig2_HTML.jpg
         isPartOf:
            name:Molecular Neurodegeneration
            issn:
               1750-1326
            volumeNumber:4
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Todd E Golde
               affiliation:
                     name:Mayo Clinic College of Medicine
                     address:
                        name:Department of Neuroscience, Mayo Clinic, Mayo Clinic College of Medicine, Jacksonville, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease
      description:Despite major advances in our understanding of the initiating factors that trigger many neurodegenerative disorders, to date, no novel disease-modifying therapies have been shown to provide significant benefit for patients who suffer from these devastating disorders. As most neurodegenerative disorders are late-onset, slowly progressive, and appear to have long relatively asymptomatic prodromal phases, it is possible that therapies optimally targeting the triggers of these disorders may have limited benefit when treatment is initiated in the symptomatic patient. Such therapies may work in the prodromal phase, or when given prophylactically, but in the symptomatic patient there simply may be too much damage to the neuronal networks to restore functionality by reducing or even eliminating the primary stressor. As functional neuronal demise and overt neuronal death are almost certainly the key factors that mediate the functional impairment, it is clear that preventing neuronal death and dysfunction will have a huge clinical benefit. Unfortunately, we lack a detailed understanding of neuronal death pathways in almost all neurodegenerative disorders. To rationally develop new disease modifying therapies that target steps in the degenerative cascade downstream of the disease trigger will require a number of factors. First, we need to refocus our basic research efforts on identifying the precise steps in the pathological cascade that lead to neuronal death in each neurodegenerative disease and, if possible, determine the relative placement of those events within a potentially very complex cascade. Second, we will need to determine which of these steps are potentially targetable. Finally, we will need to develop novel therapies that interfere with these steps and demonstrate that such therapies alone, or in combination with therapies that target the trigger of these devastating diseases, have clinical benefit.
      datePublished:2009-02-04T00:00:00Z
      dateModified:2009-02-04T00:00:00Z
      pageStart:1
      pageEnd:7
      license:http://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1750-1326-4-8
      keywords:
         Amyotrophic Lateral Sclerosis
         Neurodegenerative Disease
         Neuronal Death
         Therapeutic Development
         Prodromal Phase
         Neurosciences
         Neurology
         Molecular Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1750-1326-4-8/MediaObjects/13024_2008_Article_72_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1750-1326-4-8/MediaObjects/13024_2008_Article_72_Fig2_HTML.jpg
      isPartOf:
         name:Molecular Neurodegeneration
         issn:
            1750-1326
         volumeNumber:4
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Todd E Golde
            affiliation:
                  name:Mayo Clinic College of Medicine
                  address:
                     name:Department of Neuroscience, Mayo Clinic, Mayo Clinic College of Medicine, Jacksonville, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Molecular Neurodegeneration
      issn:
         1750-1326
      volumeNumber:4
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Mayo Clinic College of Medicine
      address:
         name:Department of Neuroscience, Mayo Clinic, Mayo Clinic College of Medicine, Jacksonville, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Todd E Golde
      affiliation:
            name:Mayo Clinic College of Medicine
            address:
               name:Department of Neuroscience, Mayo Clinic, Mayo Clinic College of Medicine, Jacksonville, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Neuroscience, Mayo Clinic, Mayo Clinic College of Medicine, Jacksonville, USA

External Links {🔗}(109)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.8s.

LINK . SPRINGER . COM {}